Balziva Kit
Product Images NDC 0555-9034

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Balziva (NDC 0555-9034). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Chemical structure diagram showing two steroid molecule formulas, corresponding to the active ingredients norethindrone and ethinyl estradiol in Balziva. The left structure includes a ketone group, and the right structure features a hydroxyl group and an alkyne substituent.*

FDA Label Image

Image 2

A bar graph showing mortality rates (number of deaths per 100,000 woman users) categorized by age groups (15-24, 25-34, 35-44, 45+). The graph compares four groups: Ever-Users (Nonsmokers), Controls (Nonsmokers), Ever-Users (Smokers), and Controls (Smokers), with mortality rates increasing markedly for the 45+ age group among Ever-Users (Smokers).*

FDA Label Image

Image 3

A forest plot chart showing effect estimates (Odds Ratios/Relative Risks) with confidence intervals from various studies on contraceptive use. The studies are listed by name and year on the left, with corresponding effect estimates plotted on an axis ranging from -1.5 to 2 on the bottom, and numerical effect estimates with confidence intervals on the right, indicating comparisons of 'Ever Use' and 'Current Use' of contraceptives.*

FDA Label Image

Image 4

Balziva kit label showing a 28-day blister pack of norethindrone and ethinyl estradiol tablets USP, 0.4 mg/0.035 mg strength. The pack includes 28 circular tablet slots arranged in a weekly grid from Sunday to Saturday across 4 weeks, with the last 7 tablets in white (likely inactive). It includes dosing instructions and storage conditions on the label. The labeler is Teva Pharmaceuticals USA, Inc., with NDC 0555-9034.*

FDA Label Image

Image 5

Balziva kit containing norethindrone and ethinyl estradiol tablets USP 0.4 mg/0.035 mg by Teva Pharmaceuticals USA, Inc. The label shows packaging for 6 blister card dispensers with 28 tablets each. The pink box includes dosage instructions and storage conditions, plus a QR code. The Teva logo and "Shaping Women's Health" slogan are also visible.*

FDA Label Image

Image 6

Balziva (norethindrone and ethinyl estradiol tablets USP) 0.4 mg/0.035 mg kit packaging label. The pink label indicates it contains 6 blister card dispensers, 28 tablets each. Manufactured by Teva Pharmaceuticals USA, Inc., the label includes dosage strength, usage warnings, barcode, and branding elements.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.